KRAS and cancer: Thus, co-inhibition of YAP–/TAZ–TEAD and KRAS G12C could be a promising combination for KRAS G12C-mutated advanced cancers when the safety and efficacy of YAP–/TAZ–TEAD inhibitors are established in ongoing early-phase clinical trials (NCT05228015, NCT04665206).